ArticleSmart molecules : open access2026
Boron-embedded multifunctional nanoplatform toward potential combined boron neutron capture therapy and immunomodulation in glioma.
Article in Smart molecules : open access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma poses a formidable therapeutic challenge due to its cellular heterogeneity, invasiveness and the protective blood-brain barrier (BBB). Boron neutron capture therapy represents a promising binary targeted radiotherapy, but its efficacy is hampered by insufficient tumor-specific accumulation, limited real-time monitoring capabilities of boron agents, and the immunosuppressive tumor microenvironment (TME). Although L-4-boronophenylalanine (BPA) is the only boron agent approved in Japan for Boron neutron capture therapy, its suboptimal tumor specificity and rapid metabolism limit effective accumulation in glioma. In this work, we engineered a theranostic strategy based on a brain-targeting nanoplatform (DM&Ce6@COF-Ang). Boron-embedded APTES-COF-1, with a high intrinsic boron content of 13.5%, served as both a therapeutic boron agent and a nanocarrier to deliver the STING agonist DMXAA (abbreviated as DM) and the fluorescent probe chlorin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.